Market news

Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Conference appearance puts STERIS (STE) in the spotlight STERIS (STE) is drawing investor attention after confirming it will participate in the Morgan Stanley Healthcare Conference in New York on September 15, 2026, with CEO Dan Carestio scheduled to present. STERIS shares trade at US$229.65 after a small pullback in the past week, while the 90 day share price return of 9.26% points to building momentum that contrasts with a year to date share price decline of 8.15% and a 1 year total...

STERIS has lagged behind the broader market over the past year, and analysts remain somewhat bullish about the stock’s prospects.

STE is betting $600 million on a new chemistry center to boost capacity and efficiency, but higher spending and execution risks loom.

STE enters fiscal 2027 with solid growth, recurring healthcare demand and better margins, but tariffs and investment needs temper the valuation case.

Detailed price information for Steris Corp (STE-N) from The Globe and Mail including charting and trades.

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how surgical equipment & consumables - diversified stocks fared in Q2, starting with STERIS (NYSE:STE).

Mohsen Sohi, Director, on August 10, 2026, sold 4,058 shares in Steris (STE) for $956,795. Following

Q2 Rundown: STERIS (NYSE:STE) Vs Other Surgical Equipment & Consumables - Diversified Stocks

STERIS (STE) has an average rating of overweight and mean price target of $265.86, according to anal

Detailed price information for Steris Corp (STE-N) from The Globe and Mail including charting and trades.

STERIS beats fiscal Q1 earnings estimates as sales rise 7.3%, but a modest revenue miss sends shares 2.4% lower after hours.

STERIS plc recently announced plans to invest US$600 million in its largest-ever manufacturing project, a 600,000 square-foot formulated chemistries Center of Excellence in North Carolina that will consolidate production and distribution and create about 335 jobs, while also increasing its quarterly dividend to US$0.69 per share for a 21st year of growth. The combination of solid fiscal 2027 first-quarter revenue growth, reaffirmed full-year guidance, and this major North Carolina...

STERIS (STE) has drawn fresh attention after committing US$600 million to a new formulated chemistries Center of Excellence in North Carolina, a major manufacturing shift that consolidates production and distribution on a single campus. See our latest analysis for STERIS. Against this backdrop, STERIS shares have risen 9.11% over the past month and 8.90% over the past quarter. The 1 year total shareholder return of 6.32% points to steadier long term compounding and suggests recent momentum...

While the top- and bottom-line numbers for Steris (STE) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Medical equipment and services company Steris (NYSE:STE) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 7.3% year on year to $1.49 billion. Its non-GAAP profit of $2.59 per share was 3.9% above analysts’ consensus estimates.

Steris (STE) delivered earnings and revenue surprises of +1.97% and -0.83%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Steris (STE) said Wednesday it will invest $600 million to construct a manufacturing and distributio

Aug 5 () - Medical equipment maker Steris said on Wednesday it will invest $600 million to build a ‌manufacturing and distribution hub in North Carolina for ‌chemicals used by healthcare and pharmaceutical customers. The company plans to move ​its existing chemicals operations from St.

DUBLIN, IRELAND, Aug. 05, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2027 first quarter ended June 30, 2026. Total revenue for the first quarter of fiscal 2027...

• This Formulated Chemistries Center of Excellence will support sterilization and disinfection for the global Healthcare and Pharmaceutical industries

STERIS (STE) To Report Earnings Tomorrow: Here Is What To Expect